Opioid use disorder is a persistent epidemic despite several FDA-approved medications for its treatment. While the pathogenesis of opioid use disorder has been classically attributed to dopamine pathways in the brain, there is emerging evidence and interest surrounding the role of inflammation and inflammatory signaling in its development and treatment. Buprenorphine has become the most prescribed medication for opioid use disorder, largely due to its ease of access and tolerability. This review aimed to better characterize contemporary knowledge of how buprenorphine modulates the human immune system and inflammatory functions in this population. A comprehensive review was conducted using 11 key databases, including Embase, MEDLINE, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov. This review captured 8177 records, and 14 studies were ultimately selected for inclusion and discussion in this review. Notably, all 14 clinical studies evaluated buprenorphine's effect on the peripheral immune system, and the majority of the studies supported the notion that initiation and maintenance of buprenorphine restore immune suppression caused by opioid use disorder. In addition, we discuss how recent and ongoing work utilizing advanced imaging and cellular technologies is advancing the understanding of how buprenorphine affects the immune and inflammatory signaling in the brain.

Download full-text PDF

Source
http://dx.doi.org/10.1111/cts.70180DOI Listing

Publication Analysis

Top Keywords

opioid disorder
16
immune system
12
human immune
8
inflammatory signaling
8
immune
5
buprenorphine's human
4
system inflammation
4
opioid
4
inflammation opioid
4
disorder
4

Similar Publications

Background: Opioid agonist treatments (OAT; methadone and buprenorphine) for opioid use disorder (OUD) reduce overdose death by more than 50%. Low population-level rates of OAT are missed opportunities to reduce OUD-related mortality.

Objective: We examined county-level OAT utilization patterns to guide state-level and county-level initiatives to improve equitable access and utilization in New York State (NYS).

View Article and Find Full Text PDF

Suboptimal care and inappropriate opioid use in chronic pain: A critical analysis of two case studies and healthcare expenditure burden.

J Opioid Manag

March 2025

SA Pharmacy, Government of South Australia, Adelaide, Australia. ORCID: https://orcid.org/0000-0003-4786-022X.

Introduction: Chronic pain is a leading cause of chronic disease in Australia, with a 2020 report indicating that one in five Australians aged over 45 experience chronic pain. The high prevalence of chronic pain accounts for significant healthcare utilization and associated costs, with the economic impact of chronic pain estimated to be AUD$139 billion in 2018.

Case Presentations: This paper uses two exemplar cases to demonstrate inadequacies within the current systems supporting those with chronic pain and the associated impacts these inadequacies have on patient outcomes and healthcare costs.

View Article and Find Full Text PDF

At-risk opioid users in a managed care insured population: Identifica-tion and outreach from a medical and pharmacy claims database.

J Opioid Manag

March 2025

Department of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore, Maryland. ORCID: https://orcid.org/0000-0002-3397-9679.

Objective: To deploy an algorithm using medical and pharmacy claims data to identify members of a managed care organization at risk for opioid misuse and provide outreach.

Methods: A retrospective review of 2019 enrollment information and prescription and medical claims data identified members aged 18-64 years with medical and pharmacy benefits and at least one paid pharmacy claim for an opioid. The most recent paid prescription claim served as the index date for each patient.

View Article and Find Full Text PDF

Objective: Methadone may cause detrimental side effects such as corrected QT (QTc) prolongation. However, methadone may be desirable in patients with advanced cancer and those with heart disease who have intractable pain. Therefore, we aimed to evaluate the safety and efficacy of initiating methadone for cancer pain in patients at high risk of methadone-induced QTc prolongation.

View Article and Find Full Text PDF

Background: The United States (US) is facing an opioid epidemic. Prescribed opioids are a contributor to this national issue. Strategies to reduce opioid prescriptions are a high priority.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!